
Six-year NATALEE results showed a 19.1% lower risk of death with Kisqali plus endocrine therapy, while Novartis shares edged lower.
Novartis said a six-year follow-up of its Phase III NATALEE trial found Kisqali plus endocrine therapy reduced the risk of death by 19.1% compared with endocrine therapy alone. The results covered patients with high-risk, hormone receptor-positive, HER2-negative early breast cancer.
The study included 5,101 patients across 20 countries. Patients had been off Kisqali for a median of 38 months when the latest analysis was conducted. The absolute overall-survival difference between the groups widened to 2.1% at six years from 1.2% at five years.
Novartis said the safety profile remained consistent with earlier analyses, with no new safety signals. As of 14:39 UTC Friday, the shares traded at 127.70 Swiss francs, down 0.92% since the previous close.
This article was produced with the help of AI technology. Based on reporting by the outlets listed above.